Madelyn D. Purcell Portfolio
Invests via Pfizer Inc | Managed by Madelyn D. Purcell
Invests via Pfizer Inc
Managed by Madelyn D. Purcell
Automatically Tracked
Madelyn D. Purcell Profile
Madelyn D. Purcell is a prominent investor-operator with extensive experience in private equity and venture capital. She has played crucial roles in identifying and nurturing growth-stage companies across technology and healthcare sectors, leveraging her background in corporate finance to drive operational efficiency. Her insight into market trends positions her as a strategic leader who bridges the gap between capital allocation and entrepreneurial execution. With an educational foundation in business administration, she remains actively engaged in mentoring emerging leaders within her network while also championing innovative projects that contribute to industry advancements.
Madelyn D. Purcell is a prominent investor-operator with extensive experience in private equity and venture capital. She has played crucial roles in identifying and nurturing growth-stage companies across technology and healthcare sectors, leveraging her background in corporate finance to drive operational efficiency. Her insight into market trends positions her as a strategic leader who bridges the gap between capital allocation and entrepreneurial execution. With an educational foundation in business administration, she remains actively engaged in mentoring emerging leaders within her network while also championing innovative projects that contribute to industry advancements.
Investment Philosophy & Strategy
Growth opportunities in emerging markets capture attention as Madelyn D. Purcell combines her operational expertise with a keen understanding of investment dynamics. Her strategic mindset drives her to seek transformative ventures, especially within technology and healthcare realms where innovation flourishes. By focusing on the scalability of businesses, she identifies potential for significant impact and sustainable returns. Active involvement in mentoring highlights her commitment to cultivating the next generation of leaders, which complements her hands-on approach to enhancing company performance. This intersection of insight and execution allows for agile decision-making aligned with long-term aspirations.
Growth opportunities in emerging markets capture attention as Madelyn D. Purcell combines her operational expertise with a keen understanding of investment dynamics. Her strategic mindset drives her to seek transformative ventures, especially within technology and healthcare realms where innovation flourishes. By focusing on the scalability of businesses, she identifies potential for significant impact and sustainable returns. Active involvement in mentoring highlights her commitment to cultivating the next generation of leaders, which complements her hands-on approach to enhancing company performance. This intersection of insight and execution allows for agile decision-making aligned with long-term aspirations.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
2.27%
Gain -0.13%
Monthly
0.1%
Yearly
1.25%
Drawdown
9.19%
$113.6M
Equity
Holdings
$113.6M
Investment
$199.04M
$62.46M
Profit -$3.65M
Realized
$147.9M
Unrealized
-$85.44M
Dividends
$0
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
-0.13%
Profit
-$3.65M
Win %
35%
This Week
Compared To Last Week
Gain
3.66%
Profit
$4.01M
Win %
35%
This Month
Compared to last month
Gain
-17.96%
Profit
-$24.86M
Win %
35%
This Year
Compared to last year
Gain
-29.64%
Profit
-$47.85M
Win %
51%
BOLT Bolt Biotherapeutics, Inc.
+57.76%
+$75,758.1 
NXTC NextCure, Inc.
+2.75%
+$5,765.11 
SENS Senseonics Holdings Inc.
+2.16%
+$347.36 
DNA Ginkgo Bioworks Holdings, Inc. Class A Common Stock
+0.93%
+$263.52 
ZNTL Zentalis Pharmaceuticals, Inc.
-7.26%
-$166,920.95 
ARVN Arvinas, Inc.
-6.61%
-$1.76M 
WVE Wave Life Sciences Ltd.
-6.42%
-$403,125 
ZURA Zura Bio Limited
-5.52%
-$105,073.99 
BHVN Biohaven Ltd.
-5.31%
-$394,403.1 
CRBU Caribou Biosciences, Inc.
-3.93%
-$103,189.48 
ORIC Oric Pharmaceuticals, Inc.
-3.35%
-$170,305.26 
CRDF Cardiff Oncology Inc.
-2.96%
-$66,318.31 
SPRO Spero Therapeutics, Inc.
-1.77%
-$47,246.96 
AGMB AgomAb Therapeutics NV American Depositary Shares
-1.73%
-$12,000 
ALLO Allogene Therapeutics, Inc.
-1.2%
-$330,480.6 
PYXS Pyxis Oncology, Inc. Common Stock
-0.88%
-$105,491.55 
CELC Celcuity Inc.
-0.32%
-$62,086.92 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 38 | Longs Won 16/38 42% | Profit Factor 1.38 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $27.33M |
| Average Win $14.17M | Best Trade (Mar 30) $147.92M | Sharpe Ratio -67.35 |
| Average Loss -$7.47M | Worst Trade (Oct 14) -$42.63M | Z-Score -0.68 (50.6%) |
| Commissions $0 | Avg. Trade Length 1y 2m 3w 5d | Expectancy $1.64M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | 36.57% | 49.5% | 59.09% | 67.01% | 73.87% | 80% | 85.57% | 90.71% | 95.5% |
| Consecutive Losing Trades | 15 | 14 | 12 | 11 | 9 | 8 | 6 | 5 | 3 | 2 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| AGMB AgomAb Therapeutics NV American Depositary Shares | 75,000 | $813,750 | $682,500 | - | -$131,250 | -16.13% | -1.728% |
| ALLO Allogene Therapeutics, Inc. | 22.03M | $46.93M | $27.21M | - | -$19.72M | -42.02% | -1.2% |
| ARVN Arvinas, Inc. | 3.46M | $66.29M | $24.93M | - | -$41.36M | -62.39% | -6.606% |
| BHVN Biohaven Ltd. | 505,645 | $18.89M | $7.03M | - | -$11.85M | -62.76% | -5.31% |
| BOLT Bolt Biotherapeutics, Inc. | 31,305 | $180,630 | $206,926.05 | - | $26,296.05 | 14.56% | +57.757% |
| CELC Celcuity Inc. | 295,652 | $3.87M | $19.32M | - | $15.45M | 399.31% | -0.32% |
| CRBU Caribou Biosciences, Inc. | 4.69M | $7.46M | $2.52M | - | -$4.93M | -66.16% | -3.929% |
| CRDF Cardiff Oncology Inc. | 2.41M | $10.47M | $2.17M | - | -$8.29M | -79.25% | -2.963% |
| DNA Ginkgo Bioworks Holdings, Inc. Class A Common Stock | 2,928 | $28,754 | $28,694.4 | - | -$59.6 | -0.21% | +0.927% |
| NXTC NextCure, Inc. | 44,347 | $259,873.54 | $215,082.95 | - | -$44,790.59 | -17.24% | +2.754% |
| ORIC Oric Pharmaceuticals, Inc. | 372,904 | $3.01M | $4.91M | - | $1.9M | 63.24% | -3.351% |
| PYXS Pyxis Oncology, Inc. Common Stock | 7.03M | $10.97M | $11.92M | - | $949,423.95 | 8.65% | -0.877% |
| SENS Senseonics Holdings Inc. | 2,171 | $22,726.03 | $16,412.76 | - | -$6,313.27 | -27.78% | +2.162% |
| SPRO Spero Therapeutics, Inc. | 2.36M | $2.43M | $2.62M | - | $188,988.31 | 7.77% | -1.77% |
| WVE Wave Life Sciences Ltd. | 1.88M | $23.19M | $5.88M | - | -$17.32M | -74.66% | -6.418% |
| ZNTL Zentalis Pharmaceuticals, Inc. | 953,834 | $2.89M | $2.13M | - | -$758,298.03 | -26.24% | -7.261% |
| ZURA Zura Bio Limited | 538,841 | $1.35M | $1.8M | - | $449,932.23 | 33.4% | -5.524% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Madelyn D. Purcell?
The largest contributions to the portfolio's profits come from the following stocks: Haleon Plc ADR - $147.92M, Tourmaline Bio Inc - $35.05M, Oric Pharmaceuticals, Inc - $11.57M, Zura Bio Limited - $7M, and Celcuity Inc - $5.43M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: BioNTech SE American Depositary Share - $56.08M, Essa Pharma Inc - $2.68M, NextCure, Inc - $889,443.25, AN2 Therapeutics, Inc - $171,671.01, and BOLT - $84,587.01. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
How stable are Madelyn D. Purcell's monthly returns?
Madelyn D. Purcell's monthly returns look fairly stable overall, although some fluctuations are still visible. The performance pattern suggests a strategy that remains reasonably controlled from month to month, even if it is not completely smooth. This may appeal to users looking for a balance between steadier results and meaningful upside potential.
Can Madelyn D. Purcell's strategy be considered aggressive or moderate?
Madelyn D. Purcell's strategy leans toward a moderately conservative profile. While there is still some exposure to market fluctuations, the overall structure and risk levels suggest a focus on maintaining stability rather than pursuing aggressive growth.
Should beginners follow Madelyn D. Purcell's strategy?
Madelyn D. Purcell's strategy appears suitable for beginners. The overall risk level, structure, and behavior of the portfolio suggest a relatively manageable approach that does not rely on extreme volatility or complex positioning. This makes it easier for less experienced users to understand and potentially follow.
2026 © Marketlog. All Rights Reserved.
